Published :
Updated :
For all latest news, follow The Financial Express Google News channel.
Square Pharmaceuticals posted double-digit year-on-year profit growth to Tk 7.27 billion in the second quarter of FY26, fueled by higher sales and substantial income from subsidiaries.
The 10 per cent year-on-year growth in earnings in the October-December quarter of FY26 pushed up the EPS of the country's largest drug manufacturer to Tk 8.20, according to the company's unaudited financial reports published on Thursday.
Square Pharma, a flagship company of Square Group, sustained growth momentum amid increased demand in the domestic market for healthcare products. It also secured higherexport earnings and higher income from subsidiaries.
Alongside operating income, interest income from investments also played a vital role in profit growth as Square Pharma had invested its surplus cash in government securities and bank deposits amid rising interest rates.
Square Pharma's consolidated revenue rose around 9 per cent year-on-year to Tk 21.79 billion in the October-December quarter last year, supported by subsidiaries-its plant in Kenya and Square Lifescience.
The drug maker's half-yearly profit also rose 16 per cent year-on-year to Tk 14.68 billion, while revenue rose 15 per cent to Tk 43.4 billion in the quarter to December last year.
Akramul Alam, head of research at Royal Capital, said Square Pharmaceuticals continued to grow in both sales and profit owing to strong consumer trust in its products.
The company's ability to produce high-quality generic medicines at relatively low costs has strengthened its competitiveness in the global market as well, Alam added.
In ensuring quality products, Square Pharma has also been putting more emphasis on research and development.
The stock of the drugmaker is considered one of the best-performing blue-chip stocks with an excellent market reputation. It is the second-largest firm in terms of market cap, and its total market capitalisation stood at Tk 195 billion as of Thursday.
The stock price closed at Tk 218.9 on Thursday, losing 0.59 per cent over the previous session on the Dhaka Stock Exchange.
Annual performance
Square Pharmaceuticals registered a 14.5 per cent year-on-year profit growth to Tk 23.97 billion in FY25, the highest-ever annual profit, driven by higher sales and earnings from subsidiaries.
The company's expanded distribution network also boosted sales by 9 per cent year-on-year to Tk 76.30 billion in FY25.
Based on the record profit, the company declared the highest-ever cash dividend-120 per cent-for the year.
babulfexpress@gmail.com